Renewal Of The Marketing Authorisation For The Medicinal Product For Human Use, National Secondoprocedura, «Destrometorfanobromidrato», Zeta Resulting Review Boards.

Original Language Title: Rinnovo dell'autorizzazione all'immissione in commercio, secondoprocedura nazionale, del medicinale per uso umano «DestrometorfanoBromidrato Zeta», con conseguente modifica stampati.

Read the untranslated law here:

Retrieved April 14, 2015 103/2015 # PV of determines the marketing authorisation of the medicinal product: DEXTROMETHORPHAN HYDROBROMIDE ZETA;
Packaging: 031317 011 ' 15 mg/1 bottle 20 ml oral drops 031317 023» solution «30 mg/10 ml 1 bottle 150 ml syrup»;
MAh: Zeta Farmaceutici S.p.A.
National Procedure.
Expiring on December 17, 2008 is renewed, with unlimited validity, the marketing authorisation subject to amendment of the summary of product characteristics, package leaflet and labelling and on condition that, on the date of entry into force of this determination, the requirements of quality, safety and efficacy are still present.
Changes must be made immediately to the summary of the product characteristics as per the package leaflet and labelling no later than six months after its publication in the Official Gazette of the Italian Republic of this determination.
In accordance with art. 80, paragraphs 1 and 3, of Legislative Decree No 219 April 24, 2006 and s leaflet and labels must be written in Italian and, limited to medicinal products marketed in the province of Bolzano, in German. The mAh avails itself of the complementary use of foreign languages, must give prior notice to the AIFA and keep available the certified translation of German texts and/or in another foreign language. In case of non-compliance with the provisions on the labelling and package leaflet shall apply sanctions under art. 82 of the Decree.
Both lots already products as of the date of publication in the official journal of the Italian Republic of this determination that the batches produced during the period referred to in article 2, paragraph 2, of the aforementioned determination, which did not indicate the changes authorized, can be kept on the market until the expiration date printed on the label of the medicine.
This determination takes effect from the day following that of its publication in the official journal of the Italian Republic and will be notified to the company holder of the marketing authorisation of the medicinal product.